肺癌实验室诊断专家共识

doi:10.6040/j.issn.1671-7554.0.2018.1020

摘要/Abstract

关键词: 肺癌, 实验室诊断, 肿瘤标志物, 分子标志物, 专家共识

Key words: Lung cancer, Laboratory diagnosis, Tumor marker, Molecular marker, Expert consensus

中图分类号:

R734.2

中国医师协会检验医师分会肺癌检验医学专家委员会. 肺癌实验室诊断专家共识[J]. 山东大学学报 (医学版), 2018, 56(10): 9-17.

[1] 支修益,石远凯,于金明.中国原发性肺癌诊疗规范(2015版)[J].中华肿瘤杂志,2015,37(1): 67-78.
[2] Ando S, Suzuki M, Yamamoto N, et al. The prognostic value of both neuron-specific enolase(NSE)and Cyfra21-1 in small cell lung cancer [J]. Anticancer Res, 2004, 24(3b): 1941-1946.
[3] Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003[J]. J Clin Oncol, 2004, 22(2): 330-353.
[4] Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer [J]. Oncology, 2001, 61(S1): 3-13.
[5] Petra S, Rudolf H, Stefan H, et al. National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Lung Cancer[J]. Tumor Biology, 2006.
[6] 中华医学会检验分会,卫生部临床检验中心,中华检验医学杂志编辑委员会. 肿瘤标志物的临床应用建议[J].中华检验医学杂志, 2012, 35(2): 103-116.
[7] 王兰兰,许化溪.临床免疫学检验[M].5版.北京:人民卫生出版社,2013.
[8] Paone G, De Angelis G, Munno R, et al. Discriminant analysis on small-cell lung cancer and non-small-cell lung cancer by means of NSE and CYFRA 21-1[J]. Eur Respir J,1995, 8(7): 1136-1140.
[9] Ebert W, Muley T. CYFRA 21-1 in the follow-up of inoperable non-small-cell lung cancer patients treated with chemotherapy[J]. Anticancer Res, 1999, 19(4A): 2669-2672.
[10] Takei Y, Minato K, Tsuchiya S, et al. CYFRA21-1: an indicator of survival and therapeutic effect in lung cancer[J]. Oncology, 1997, 54(1): 43-47.
[11] 中国合格评定国家认可委员会. CNAS-CL02:2012 医学实验室质量和能力认可准则[EB/OL]. https://www.cnas.org.cn/rkgf/sysrk/jbzz/2013/12/750592.shtml, 2013-12-11/2018-09-03.
[12] 中国合格评定国家认可委员会. CNAS-CL38:2012 医学实验室质量和能力认可准则在临床化学检验领域的应用说明[EB/OL]. https://www.cnas.org.cn/rkgf/sysrk/rkyyzz/2014/05/782592.shtml, 2014-05-06/2018-09-03.
[13] 李金明,刘辉.临床免疫学检验技术[M].北京:人民卫生出版社,2015.
[14] 唐古生,沈茜.临床免疫检测的干扰因素和解决办法[A].中华医学会,中华医学会第七次全国中青年检验医学学术会议论文汇编[C] , 2012: 33-34.
[15] 中国医师协会肿瘤医师分会,中国抗癌协会肿瘤临床化疗专业委员会.中国表皮生长因子受体基因敏感性突变和间变淋巴瘤激酶融合基因阳性非小细胞肺癌诊断治疗指南(2015版)[J]. 中华肿瘤杂志, 2015, 37(10): 796-799.
[16] 中华人民共和国国家卫生和计划生育委员会. 药物代谢酶和药物作用靶点基因检测技术指南(试行)和肿瘤个体化治疗检测技术指南(试行)[EB/OL]. 国卫医医护便函〔2015〕240号,http://www.moh.gov.cn/yzygj/s3593/201507/fca7d0216fed429cac797cdafa2ba466.shtml, 2015-07-31/2018-09-03.
[17] 中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家组.中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家共识(2016版)[J].中华病理学杂志, 2016, 45(4): 217-220.
[18] 中国专家共识专家组.非小细胞肺癌血液EGFR基因突变检测中国专家共识[J].中华医学杂志, 2015, 95(46): 3721-3726.
[19] Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology[J]. Arch Pathol Lab Med, 2013, 137(6): 828-860.
[20] Thomas A, Liu SV, Subramaniam DS, et al. Refining the treatment of NSCLC according to histological and molecular subtypes[J]. Nat Rev Clin Oncol, 2015, 12(9): 511-526.
[21] Cheng L, Alexander RE, Maclennan GT, et al. Molecular pathology of lung cancer: key to personalized medicine[J]. Mod Pathol, 2012, 25(3): 347-369.
[22] Piotrowska Z, Sequist LV. Epidermal growth factor receptor-mutant lung cancer: new drugs, new resistance mechanisms, and future treatment options[J]. Cancer J, 2015, 21(5): 371-377.
[23] Zhang K, Yuan Q. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer[J]. J Cancer Res Ther, 2016, 12(Supplement): C131-C137.
[24] Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance[J]. Cancer Discov, 2017, 7(2): 137-155.
[25] Zhang J, Park D, Shin DM, et al. Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities[J]. Acta Biochim Biophys Sin(Shanghai), 2016, 48(1): 11-16.
[26] 王恩华,朱明华,步宏,等.非小细胞肺癌靶向药物治疗相关基因检测的规范建议[J].中华病理学杂志, 2016, 45(2): 73-77.
[27] Zhang S, Xia B, Jiang H, et al. Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology[J]. Oncotarget, 2016, 7(31): 50477-50489.
[28] Wang W, Song Z, Zhang Y. A comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance[J]. Cancer Med, 2017, 6(1): 154-162.
[29] Malapelle U, Pisapia P, Rocco D, et al. Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients[J]. Transl Lung Cancer Res, 2016, 5(5): 505-510.
[30] Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA[J]. Nat Rev Cancer, 2017, 17(4): 223-238.
[31] Normanno N, Denis MG, Thress KS, et al. Guide to detecting epidermal growth factor receptor(EGFR)mutations in ctDNA of patients with advanced non-small-cell lung cancer[J]. Oncotarget, 2017, 8(7): 12501-12516.

相关文章 15

[1]	韩靖,贾春玲. 肺癌患者胸外手术前治疗牙周基础疾病对预防术后肺炎发生的效果评价[J]. 山东大学学报 (医学版), 2022, 60(9): 113-118.
[2]	高中霞,张铭,樊明德,谭晨阳,王梦迪,王超,樊跃飞,丁守銮,王成伟. 伽玛刀治疗81例肺癌脑转移瘤的疗效及预后因素[J]. 山东大学学报 (医学版), 2022, 60(8): 44-49.
[3]	秦静,杨飞,陈谦,夏涵岱,刘延国,王秀问. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报 (医学版), 2022, 60(7): 74-82.
[4]	王福立,孙银萍,秦杰,荣建胜. DC-CIK细胞联合EGFR-TKI治疗35例老年晚期EGFR突变肺癌的效果[J]. 山东大学学报 (医学版), 2022, 60(7): 110-117.
[5]	陈兆波,方敏,薛浩然,刘春艳. 去泛素化酶USP35促进非小细胞肺癌细胞迁移和侵袭[J]. 山东大学学报 (医学版), 2022, 60(4): 30-37.
[6]	于金明,颜薇薇,陈大卫. 肺癌放射免疫新实践[J]. 山东大学学报 (医学版), 2021, 59(9): 1-8.
[7]	张煜,唐兴,马海涛,蒋威. 荧光染色技术在胸腔镜肺段切除术中的价值[J]. 山东大学学报 (医学版), 2020, 58(12): 38-42.
[8]	张喜琴,祝守慧,刘宁,王玉,陈家帧,胡旭东. PEG-rhG-CSF对80例小细胞肺癌同步放化疗预防中性粒细胞减少的临床观察[J]. 山东大学学报 (医学版), 2020, 58(12): 43-46.
[9]	刘小璟,夏西燕,肖珂,陈文丹,庄学伟. 外泌体lncRNA OGFRP1在84例非小细胞肺癌中的表达及临床意义[J]. 山东大学学报 (医学版), 2020, 58(11): 71-75.
[10]	曹冬焱,毕晓宁,沈铿. 抗苗勒氏管激素在妇科肿瘤领域的应用前景[J]. 山东大学学报 (医学版), 2018, 56(5): 8-12.
[11]	中国医师协会检验医师分会妇科肿瘤检验医学专家委员会. 妇科肿瘤标志物应用专家共识[J]. 山东大学学报 (医学版), 2018, 56(10): 3-8.
[12]	李星凯,刘战业,姜运峰,李军. 原发性中央型和周围型肺鳞癌临床病理学及预后差异[J]. 山东大学学报（医学版）, 2017, 55(9): 73-78.
[13]	曾海燕,李睿,孙新东,谢鹏,孟雪,范秉杰,李万龙,袁双虎. 局限期小细胞肺癌患者预防性脑照射后脑转移的关联分析:双中心研究[J]. 山东大学学报（医学版）, 2017, 55(7): 61-66.
[14]	孙启晶,陈方方,李春晓,张才擎. PNI及HGB评估中晚期非小细胞肺癌患者预后的临床价值[J]. 山东大学学报（医学版）, 2017, 55(4): 55-59.
[15]	李笑莹,刘芳,车海杰,张尽晖. 肿瘤标志物预测孤立性肺结节恶性概率模型的建立与初步评价[J]. 山东大学学报（医学版）, 2017, 55(4): 60-64.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed